Abstract
Background: Desmoid tumors have an extremely variable natural history. The uncertainty behind desmoid behavior reflects the complexity, which subtends its development and non-linear advancement. Apart from Wnt- βcatenin mutation, estrogen receptors, and COX-2 overexpression, little is known about the ability of desmoids to grow and recur while being unable to metastasize. Several tumors have been shown to express the CXCR4/CXCR7/CXCL12 axis, whose functions are essential for tumoral development.
Aims: This study aimed to investigate the expression of the CXCR4/CXCR7/CXCL12 axis in primary desmoid tumors and discuss the potential role of this key-signaling as an antiangiogenic therapeutic strategy.
Methods: In this study, 3 μm-thick consecutive sections from each formalin-fixed and paraffin-embedded tissue block were treated with mouse monoclonal antibodies developed against CD34, CXCR4, CXCR7, and CXCL12.
Results: Two distinct vessel populations: CXCR4+ and CXCR4- vessels, have been found. Similarly, chemokine receptor CXCR7 expression in the entire desmoid tumor series positively stained a portion of tumor-associated vessels, identifying two distinct subpopulations of vessels: CXCR7+ and CXCR7- vessels. All 8 neoplastic tissue samples expressed CXCL12. Immunohistochemical positivity was identified in both stromal and endothelial vascular cells. Compared to CXCR4 and CXCR7, the vast majority of tumor-associated vessels were found to express this chemokine.
Conclusion: It is the first time, as per our knowledge, that CXCR4/CXCR7/CXCL12 axis expression has been identified in a desmoid type-fibromatosis series. CXCL12 expression by neoplastic cells, together with CXCR4 and CXCR7 expression by a subgroup of tumor-associated vessels, was detected in all desmoid tumor tissue samples examined. Since chemokines are known contributors to neovascularization, CXCR4/CXCR7/CXCL12 axis may play a role in angiogenesis in this soft-tissue tumor histotype, thereby supporting its growth.
Keywords: Desmoid tumors, angiogenesis, chemokines, CXCR4, CXCR7, CXCL12, therapy.
[http://dx.doi.org/10.1158/0008-5472.CAN-10-1656] [PMID: 20841474]
[http://dx.doi.org/10.1007/s00432-020-03498-y] [PMID: 33452581]
[http://dx.doi.org/10.2217/fon-2021-0003] [PMID: 34227399]
[http://dx.doi.org/10.1093/ajcp/77.6.665] [PMID: 7091046]
[http://dx.doi.org/10.1002/ijc.25664] [PMID: 20830713]
[http://dx.doi.org/10.1002/gcc.22272] [PMID: 26171757]
[http://dx.doi.org/10.1097/CCO.0000000000000374] [PMID: 28489620]
[http://dx.doi.org/10.1093/ajcp/aqv094] [PMID: 27124915]
[http://dx.doi.org/10.1200/JCO.2017.75.8482] [PMID: 29220303]
[http://dx.doi.org/10.1002/cncr.32555] [PMID: 31691276]
[http://dx.doi.org/10.1200/JCO.2010.33.5489] [PMID: 21844500]
[http://dx.doi.org/10.1097/SLA.0b013e31828c8a30] [PMID: 23532110]
[http://dx.doi.org/10.1245/s10434-020-09395-5] [PMID: 33386543]
[http://dx.doi.org/10.1016/S1470-2045(19)30543-1] [PMID: 31578997]
[http://dx.doi.org/10.1158/0008-5472.CAN-04-1443] [PMID: 15466206]
[http://dx.doi.org/10.1158/1078-0432.CCR-10-3322] [PMID: 21447727]
[http://dx.doi.org/10.1056/NEJMoa1805052] [PMID: 30575484]
[http://dx.doi.org/10.1016/S0076-6879(05)07047-3] [PMID: 16757355]
[http://dx.doi.org/10.1056/NEJMoa0708857] [PMID: 18650514]
[http://dx.doi.org/10.1056/NEJMoa060655] [PMID: 17215530]
[http://dx.doi.org/10.1007/s40259-013-0049-y] [PMID: 23818056]
[http://dx.doi.org/10.1158/1078-0432.CCR-16-2131] [PMID: 28223275]
[http://dx.doi.org/10.3389/fonc.2018.00248] [PMID: 30013950]
[http://dx.doi.org/10.1016/j.bbrc.2007.05.182] [PMID: 17559806]
[http://dx.doi.org/10.1002/jor.1100180419] [PMID: 11052503]
[http://dx.doi.org/10.1016/j.devcel.2010.05.012] [PMID: 20627072]
[http://dx.doi.org/10.1016/j.cell.2011.02.013] [PMID: 21376230]
[http://dx.doi.org/10.1038/onc.2015.139] [PMID: 25961926]
[http://dx.doi.org/10.1007/s11912-019-0839-6] [PMID: 31418125]
[http://dx.doi.org/10.1038/nm1075] [PMID: 15235597]
[http://dx.doi.org/10.1084/jem.20030267] [PMID: 14597738]
[http://dx.doi.org/10.1080/mic.10.3-4.359.370] [PMID: 12851652]
[http://dx.doi.org/10.1016/j.ejca.2019.11.013] [PMID: 32004793]
[http://dx.doi.org/10.1016/j.jss.2010.10.037] [PMID: 21195420]
[http://dx.doi.org/10.1158/0008-5472.CAN-06-1377] [PMID: 17178882]
[http://dx.doi.org/10.1158/1535-7163.MCT-06-0595] [PMID: 17575107]
[http://dx.doi.org/10.1158/1078-0432.CCR-12-0552] [PMID: 22929805]
[http://dx.doi.org/10.3389/fphar.2020.574667] [PMID: 33363463]
[http://dx.doi.org/10.1002/mc.22916] [PMID: 30259564]